Is FFR/iFR the same in the LAD and LCx in isolated LMCA disease? We are excited to share our #disruptive findings, online @CircIntv today https://t.co/XKpYIxgKT3 ‼️ All pressure-based indices are LOWER in the LAD than in LCx (misclassification 21% by FFR 28% by iFR)

Just a few of the photos from the INOCA 2025 London Meeting - GREAT presentations, great networking, great organisation and GREAT live cases too! 🤩 You can read more about the meeting here - https://t.co/5mJ2h1rqhK

Milestone alert 🚨: The team at Guys and St Thomas' NHS Foundation Trust have now randomised their 11th participant—taking the BCIS-4 study to a total of 50! A fantastic achievement powered by collaboration and commitment 💪 #BCIS4 #ClinicalTrials @GSTTnhs @divaka_perera

Is CABG better than PCI for patients with severe LV impairment? @NIHRresearch @BCIS4Trial seeks to answer this question and team @GSTTnhs enrolled the 50th UK patient today! Congratulations to @AishSinha1 @DrMattRyan @DrHaseebRahman1 @AntonisPavlidi3 @divaka_perera et al

Watch the latest OPCI Journal Club! Divaka Perera presents “Pressure-Derived Indices in the Left Main Coronary Artery: Insights from Comprehensive In Vivo Hemodynamic Studies of Diseased and Unobstructed Vessels.” Featuring panelists @ziadalinyc @DrAllenJ @ESHLOF @JWMoses.

Session Four of #INOCA2025 looks at how we can build better services and diagnostics for #ANOCA patients. Talks include: - Patient Stories - Setting Up a Service – Dr. Mark Mariathas, Dr. Tusha Kotecha - Non-Invasive Diagnostics: CMR – Prof. Amedeo Chiribiri - PET, Echo Doppler,

It’s all down to our collaborative multi-disciplinary team of cardiologists, cardiovascular surgeons, research nurses, research fellows and AHPs, who prioritise patient care and value research! @GSTTnhs @NIHRresearch @kingscardio @REVIVED_BCIS2 @CHIP_BCIS3 @UKheartresearch

This will be another great session when we will hear about why the @NIHRresearch-@TheBHF established the UK CMD workstream, updates from other international networks and what is expected of the workstream by funders, patients, industry and clinicians! still a few places left!

Ready to sharpen your skills? Session Two of INOCA 2025 features hands-on insights into invasive testing: 💡 How to Do Bolus Thermodilution – Dr. @ruperRupert Williams 💡 How to Do Continuous Thermodilution – Dr. Tom Keeble 💡 How to Do Doppler – Dr. Tim van de Hoef 🎥 Plus,

📣 applications invited for 3-year clinical/translational research fellowships (PhD/MD) @kingscardio @KingsCollegeLon Projects in microvascular dysfunction, ischaemic cardiomyopathy + more. In-person/on-line OPEN DAY 29th Sept ‘25. Register via: https://t.co/MnHEqNiazo

If you see patients with INOCA and/or are interested in learning more about it then this is THE meeting to attend!! Fantastic international faculty. Brilliant and clinically relevant sessions. And a chance to showcase your work!!

🔊2 weeks to go to INOCA 2025! 📍London SE1 7AR @TheBHF @NIHRresearch Incredible international faculty How to sessions Guideline updates Informative talks Debates Live cases Lived experience Innovations in INOCA ‼️Register ASAP https://t.co/UjWmimT9K9

New #REVIVED imaging *head to head*: CMR vs echo 🫀 🔺CMR volumes were higher + LVEF was lower 🔺ESVi was predictive of outcomes, LVEF was not 🚨Only 7.5% of paired LVEF values fell within 5% of each other! 🚨A third had CMR LVEF<35% and echo LVEF≥35% https://t.co/Qyf8PAUrq4

3️⃣ Why was there no prognostic impact of PCI? Scar a stronger driver of prognosis/ fatal arrhythmia than ischaemia or recurrent MI. Degree of ischaemia correlated poorly with outcome even in OMT group Completeness of revasc did not have an effect on outcome jn PCI group

2️⃣ How symptomatic were patients? QoL was very limited. KCCQ overall summary score (median) was 62, similar to patients in STICH and worse than in DAPA-HF or PARADIGM-HF trials QoL improved with time with medical therapy; PCI did not offer incremental symptomatic benefit.

3 years on, excellent summary of key insights by @divaka_perera 1️⃣ How much ischaemia/CAD was present/treated? 30% of LV (~5 segments) ischaemic BCIS jeopardy score 10 (max possible=12) Left main disease in 14% 85% of viable myocardium revascularised (if assigned to PCI)

@divaka_perera makes a strong case: routine #PCI should not be performed in asymptomatic pts with LV dysfunction (even with viability). It does NOT improve prognosis ‼️ Evidence should guide practice: The earth is not flat 🌎 #ESCCongress @escardio @drjohnm

No trial better explains the importance of evidence than REVIVED BCIS. It boggles my mind that it was negative @divaka_perera is correct, but try telling 99% of American cardiologists We still cath new LV dys pts TO FIND LESIONS TO REVASC despite negative trials #ESC2025

Proud to be part of the #APEX team running the Interventional Cardiology Workshop at Asiri Central Hospital on Saturday 2nd August, during the 2025 Sri Lanka College of Cardiology academic sessions in Colombo. @DrPeterOKane @twj1974 @JehangirDin @SmithElliotjs @VP_Med

@UKheartresearch @REVIVED_BCIS2 @JACCJournals ➡️ Among patients with EF <30%, those with more scar have significantly worse outcomes ➡️ Even in those with slightly better EF (30-40), we can identify those at higher risk by looking at the volume and pattern of their scar

Unravelling the contributions of ischaemia and scar in arrhythmogenesis - these two papers give us the answers!⚡️🫀 Ischaemia paper 🔗 https://t.co/aWcXChzTxz @divaka_perera @achir76 @sohaibnazir @webmd11 @drjohnm @LambiasePier @SVRaoMD @aayshacader @DrMarthaGulati @TCTMD_Yael